1. FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer. Issue 11 (10th April 2022) Authors: Royce, Melanie; Osgood, Christy; Mulkey, Flora; Bloomquist, Erik; Pierce, William F.; Roy, Arpita; Kalavar, Shyam; Ghosh, Soma; Philip, Reena; Rizvi, Fatima; Mixter, Bronwyn D.; Tang, Shenghui; Pazdur, Richard; Beaver, Julia A.; Amiri-Kordestani, Laleh Journal: Journal of clinical oncology Issue: Volume 40:Issue 11(2022) Page Start: 1155 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy. (19th April 2017) Authors: Ning, Yang‐Min; Suzman, Daniel; Maher, V. Ellen; Zhang, Lijun; Tang, Shenghui; Ricks, Tiffany; Palmby, Todd; Fu, Wentao; Liu, Qi; Goldberg, Kirsten B.; Kim, Geoffrey; Pazdur, Richard Journal: Oncologist Issue: Volume 22:Number 6(2017) Page Start: 743 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy. (June 2017) Authors: Ning, Yang‐Min; Suzman, Daniel; Maher, V. Ellen; Zhang, Lijun; Tang, Shenghui; Ricks, Tiffany; Palmby, Todd; Fu, Wentao; Liu, Qi; Goldberg, Kirsten B.; Kim, Geoffrey; Pazdur, Richard Journal: Oncologist Issue: Volume 22:Number 6(2017) Page Start: 743 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy. (12th December 2018) Authors: Suzman, Daniel L.; Agrawal, Sundeep; Ning, Yang‐min; Maher, V. Ellen; Fernandes, Laura L.; Karuri, Stella; Tang, Shenghui; Sridhara, Rajeshwari; Schroeder, Jason; Goldberg, Kirsten B.; Ibrahim, Amna; McKee, Amy E.; Pazdur, Richard; Beaver, Julia A. Journal: Oncologist Issue: Volume 24:Number 4(2019) Page Start: 563 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti‐Angiogenic Therapy and Exploratory Predictive Biomarker Analysis. (23rd February 2017) Authors: Xu, James Xunhai; Maher, V. Ellen; Zhang, Lijun; Tang, Shenghui; Sridhara, Rajeshwari; Ibrahim, Amna; Kim, Geoffrey; Pazdur, Richard Journal: Oncologist Issue: Volume 22:Number 3(2017) Page Start: 311 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti‐Angiogenic Therapy and Exploratory Predictive Biomarker Analysis. (March 2017) Authors: Xu, James Xunhai; Maher, V. Ellen; Zhang, Lijun; Tang, Shenghui; Sridhara, Rajeshwari; Ibrahim, Amna; Kim, Geoffrey; Pazdur, Richard Journal: Oncologist Issue: Volume 22:Number 3(2017) Page Start: 311 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer. (20th October 2020) Authors: Arora, Shaily; Balasubramaniam, Sanjeeve; Zhang, Hui; Berman, Tara; Narayan, Preeti; Suzman, Daniel; Bloomquist, Erik; Tang, Shenghui; Gong, Yutao; Sridhara, Rajeshwari; Turcu, Francisca Reyes; Chatterjee, Deb; Saritas‐Yildirim, Banu; Ghosh, Soma; Philip, Reena; Pathak, Anand; Gao, Jennifer J.; A... Journal: Oncologist Issue: Volume 26:Number 1(2021) Page Start: e164 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer. (17th November 2020) Authors: Anscher, Mitchell S.; Chang, Elaine; Gao, Xin; Gong, Yutao; Weinstock, Chana; Bloomquist, Erik; Adeniyi, Oluseyi; Charlab, Rosane; Zimmerman, Sarah; Serlemitsos‐Day, Maritsa; Ning, Yang Min; Mayrosh, Ruth; Fuller, Barbara; Trentacosti, Ann Marie; Gallagher, Pamela; Bijwaard, Karen; Philip, Reena;... Journal: Oncologist Issue: Volume 26:Number 2(2021) Page Start: 139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients. Issue 30 (20th October 2022) Authors: Fourie Zirkelbach, Jeanne; Shah, Mirat; Vallejo, Jonathon; Cheng, Joyce; Ayyoub, Amal; Liu, Jiang; Hudson, Rachel; Sridhara, Rajeshwari; Ison, Gwynn; Amiri-Kordestani, Laleh; Tang, Shenghui; Gwise, Thomas; Rahman, Atiqur; Pazdur, Richard; Theoret, Marc R. Journal: Journal of clinical oncology Issue: Volume 40:Issue 30(2022) Page Start: 3489 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer. (2021) Authors: Mason, Jeremy; Gong, Yutao; Amiri-Kordestani, Laleh; Wedam, Suparna; Gao, Jennifer J.; Prowell, Tatiana M.; Singh, Harpreet; Amatya, Anup; Tang, Shenghui; Pazdur, Richard; Kuhn, Peter; Blumenthal, Gideon M.; Beaver, Julia A. Journal: JCO Clinical Cancer Informatics Issue: Volume 5(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗